Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed (LENDEXAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01194791|
Recruitment Status : Completed
First Posted : September 3, 2010
Last Update Posted : April 25, 2017
Primary outcome measure:
- Hematologic response rate to the association of Lenalidomide, Cyclophosphamide and Dexamethasone.
Secondary outcome measures:
- Organ response rate.
- Predictors of response (cardiac biomarkers, serum free light chains).
- Safety (type, frequency, severity and relationship of adverse events to the study drug).
- Duration of response.
- Time to progression.
- Overall survival
|Condition or disease||Intervention/treatment||Phase|
|Primary Systemic Amyloidosis||Drug: Lenalidomide Drug: Cyclophosphamide Drug: Dexamethasone||Phase 2|
It is a multicenter, single arm treatment, phase II study of the combination in one treatment arm with Lenalidomide, Cyclophosphamide and Dexamethasone.
Subjects who qualify for participation will receive lenalidomide plus dexamethasone and cyclophosphamide in 4-week cycles. Subjects will be seen (study visits) every 2 weeks for the first 3 cycles of therapy and monthly thereafter.
Cycles of lenalidomide/dexamethasone/cyclophosphamide will consists of lenalidomide 15 mg by mouth for 21 days followed by 7 days rest and 300 mg/m2 of cyclophosphamide on days 1 and 8 plus oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals. Patients will be treated with 6 cycles of therapy with the option to continue beyond as long there is evidence of response. In this case the dose of lenalidomide will be the same and the dose of the dexamethasone will be administered only on days 1 to 4 of each cycle and the dose of cyclophosphamide only day 1 during 6 cycles. After 12 cycles if the patients remaining in response, will be treated with 10 mg/day, cyclophosphamide day 1, and dexamethasone will be administered on days 1 to 4 of each cycle.
For the first 3 cycles, patients will be followed for adverse events with hematologic control every 2 weeks and monthly thereafter. Patients will be required to have a blood work-up including total serum protein and serum protein electrophoresis, urine protein studies and a clinical visit before each cycle. Organ involvement will be assessed every 4 cycles during the first year of therapy. Hematologic response will be assessed every 3 months and organ response every 6 months after the first year of treatment.
Treatment modifications will be based on adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE Version 3.0).
There will be 30 patients enrolled.
The trial consists of three periods: pre-treatment, treatment and follow up period.
Pre-treatment phase: include the enrolment visit in order to determine if the patient is eligible to participate in the study. The patient will sign the Informed Consent Form to take part in the study, and will receive detailed information about the treatment, its benefits and risks.
Treatment phase: include the 12 cycles of 28 days treatment with Lenalidomide, Cyclophosphamide and Dexamethasone as induction therapy followed with low doses of Lenalidomide and Dexamethasone during three years until progression or unacceptable toxicity levels.
Follow up phase: Once the clinical trial has finished, patients will be followed during usual clinical practice visits where progression, free survival and overall survival will be evaluated.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicentric, Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed, Not Candidates for Hematopoietic Stem Cell Transplantation|
|Study Start Date :||October 2010|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||December 2016|
|Experimental: Lenalidomide, Cyclophosphamide and Dexamenthasone||
Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
Other Name: LendexalDrug: Cyclophosphamide
Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cyclesDrug: Dexamethasone
Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
- Hematologic response rate to the association of Lenalidomide, Cyclophosphamide and Dexamethasone [ Time Frame: 6 months ]
- Organ response rate [ Time Frame: 6 months ]
- Predictors of response (cardiac biomarkers, serum free light chains) [ Time Frame: 5 years ]
- Safety and tolerability [ Time Frame: 5 years ]
- Duration of response [ Time Frame: 10 years ]
- Time to progression [ Time Frame: 5 years ]
- Overall survival [ Time Frame: 10 yeras ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01194791
|Hospital Universitario de Canarias|
|Tenerife, Islas Canarias, Spain|
|Hospital Germans Trias i Pujol|
|Hospital de la Santa Creu i Sant Pau|
|Hospital Clínico San Carlos|
|Hospital Doce de Octubre|
|Hospital Morales Messeguer|
|Hospitalm Clínico de Salamanca|
|Hospital La Fe|
|Hospital Lozano Blesa|
|Study Chair:||Bladé Joan, Dr||Hospital Clinic of Barcelona|